Bicycle Therapeutics PLC (BCYC) FinancialsBCYCFinancialBicycle Therapeutics PLC

Evaluating the bottom line, Bicycle Therapeutics PLC maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -8684.90%, while the net margin is -8002.07%. These profitability ratios, combined with a Return on Equity (ROE) of -32.30%, provide a clear picture of how effectively BCYC converts its operational activities into shareholder value.

In the context of the broader market, BCYC competes directly with industry leaders such as TTRX and AMRN. With a market capitalization of $303.07M, it holds a significant position in the sector. When comparing efficiency, BCYC's gross margin of 100.00% stands against TTRX's N/A and AMRN's 35.51%. Such benchmarking helps identify whether Bicycle Therapeutics PLC is trading at a premium or discount relative to its financial performance.

Bicycle Therapeutics has shown a gross margin of 100% in recent quarters, but it also reported a net loss of $50.33 million in Q2 2026, indicating ongoing profitability challenges. The current ratio remains strong at 12.08, suggesting good short-term liquidity.